Symbio Clinical Research
Symbio Clinical Research is recorded as a service provider in 11 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 11 of 11 trials · Latest update first
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on disease activity in patients with Hidradenitis Suppurativa (HS)
Sponsor Citryll B.V.
- Start (EU)
- Latest update
- Estimated end
Proof-of-Concept Evaluation of Immunological Assays Using Human Blood and Urine Samples after Vaccination with StroVac
Sponsor Strathmann GmbH & Co. KG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for induction of histological remission in adults with eosinophilic esophagitis
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
Double-blind, randomised clinical study comparing efficacy and safety of Clindamycin/Tretinoin Gel (10 mg/g + 0.25 mg/g) (Test) vs. Acnatac(R) 10 mg/g + 0.25 mg/g Gel (Reference) vs. Vehicle in patients with papulopustular acne
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis
Sponsor Innocare Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Sympomatic Despite Treatment with H1 Antihistamines and/or Omalizumab, or who Cannot Tolerate Omalizumab
Sponsor Jasper Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Ointment (Test) vs. Advantan® 0.1% Ointment (Reference) vs. Vehicle in patients with mild to moderate atopic dermatitis
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Cream (Test) vs. Advantan(R) 0.1% Cream (Reference) vs. Vehicle in patients with mild to moderate atopic dermatitis
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomised clinical study comparing efficacy and safety of Ivermectin 10 mg/g Cream (Test) vs. Soolantra® 10 mg/g Cream (Reference) vs. Vehicle in patients with papulopustular rosacea
Sponsor Dermapharm AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase-2, multi-centre, prospective, randomized, standard-of-care plus placebo-controlled, patient and central evaluator blinded, parallel arm, clinical study to evaluate safety, tolerability and efficacy of the recommended phase-2 dose of AUP1602-C in two dosing frequencies as a topical treatment for non-healing neuro-ischemic diabetic foot ulcers
Sponsor Aurealis Oy
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Symbio Clinical Research?
The 2026-10-09 snapshot links Symbio Clinical Research to 11 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Regulatory services, Medical writing, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Symbio Clinical Research?
The most frequently recorded therapeutic areas are Dermatology, Gastroenterology, Immunology, Infectious Disease. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Symbio Clinical Research conducted?
The linked trials record locations in 9 countries, including Germany, Poland, Austria, Spain, Belgium. These are trial locations, not confirmed office locations or countries where Symbio Clinical Research delivered services.
What can this page tell me about Symbio Clinical Research's trial experience?
Browse 11 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Symbio Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Symbio Clinical Research GmbH